PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1128-1136

  Vanaja, Donkena Krishna ^a   Ballman, Karla V ^a   Morlan, Bruce W ^a   Cheville, John C ^a   Neumann, Roxann M ^a   Lieber, Michael M ^a   Tindall, Donald J ^a   Young, Charles Y F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BIOLOGICAL MARKER; BISULFITE; DNA; MESSENGER RNA; PROTEIN PDLIM4; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; C21ORF63 GENE; CANCER DIAGNOSIS; CANCER GROWTH; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; FABP5 GENE; FLJ14084 GENE; GENE; GENE REPRESSION; GLEASON SCORE; GSTP1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIAA1210 GENE; MALE; MLP GENE; NUCLEOTIDE SEQUENCE; PDLIM4 GENE; PRIMA1 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PTGS2 GENE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SORBS1 GENE; SOX4 GENE; SVIL GENE; TRANSCRIPTION REGULATION; TU3A GENE; TUMOR SUPPRESSOR GENE;

AGED; AZACITIDINE; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA-BINDING PROTEINS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644768137     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2072     Document Type: Article

References (45)

1. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
2. Laird PW. Cancer epigenetics. Hum Mol Genet 2005;14Spec No 1:R65-76.
3. Lodygin D, Epanchintsev A, Menssen A, et al. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005;65: 4218-27.
4. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
5. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: Where do they come from? Cancer Sci 2005;96:206-11.
6. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63.
7. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol 2004;14:427-32.
8. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22:4632-42.
9. Nakayama M, Gonzalgo ML, Yegnasubramanian S, et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004;91:540-52.
10. Li LC, Okino ST, Dahiya R. DNA methylation in prostate cancer. Biochim Biophys Acta 2004;1704:87-102.
11. Millar DS, Ow KK, Paul CL, et al. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 1999; 18:1313-24.
12. Jeronimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004;10:8472-8.
13. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037-43.
14. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005;11:4097-106.
15. Tokumaru Y, Harden SV, Sun DI, et al. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004;10:5518-22.
16. Kang GH, Lee S, Lee HJ, et al. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202:233-40.
17. Balch C, Montgomery JS, Paik HI, et al. New anticancer strategies: epigenetic therapies and biomarkers. Front Biosci 2005;10:1897-931.
18. Vanaja DK, Cheville JC, Iturria SJ, et al. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003;63:3877-82.
19. Blute ML, Bergstralh EJ, Iocca A, et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-25.
20. Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003;101:1270-6.
21. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
22. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
23. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64:1975-86.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
25. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
26. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
27. Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683-8.
28. LaTulippe E, Satagopan J, Smith A, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002;62:4499-506.
29. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
30. Shyamsundar R, Kim YH, Higgins JP, et al. A DNA microarray survey of gene expression in normal human tissues. Genome Biol 2005;6:R22.
31. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer Proc Natl Acad Sci U S A 2004; 101:811-6.
32. Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9.
33. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002;99:3740-5.
34. Antequera F. Genomic specification and epigenetic regulation of eukaryotic DNA replication origins. EMBO J 2004;23:4365-70.
35. Jones PA. An epigenetic approach for finding tumor suppressors. Cell Cycle 2003;2:25-6.
36. Ting HJ, HuYC, Chang C. Actin monomer enhances supervillin-modulated androgen receptor transactivation. Biochem Biophys Res Commun 2004;319: 393-6.
37. Ting HJ, Yeh S, Nishimura K, et al. Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc Natl Acad Sci U S A 2002;99:661-6.
38. Vallenius T, Scharm B, Vesikansa A, et al. The PDZ-LIM protein RIL modulates actin stress fiber turnover and enhances the association of α-actinin with F-actin. Exp Cell Res 2004;293:117-28.
39. Kiess M, Scharm B, Aguzzi A, et al. Expression of ril, a novel LIM domain gene, is down-regulated in Hras-transformed cells and restored in phenotypic revenants. Oncogene 1995;10:61-8.
40. Bashirova AA, Markelov ML, Shlykova TV, et al. The human RIL gene: mapping to human chromosome 5q31.1, genomic organization and alternative transcripts. Gene 1998;210:239-45.
41. Goessl C, Muller M, Heicappell R, et al. Methylation-specific PCR for detection of neoplastic DNA in biopsy washings. J Pathol 2002;196:331-4.
42. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001;93: 1747-52.
43. Lin X, Tascilar M, Lee WH, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001;159:1815-26.
44. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8: 282-8.
45. Bykov VJ, Zache N, Stridh H, et al. PRIMA-1 (MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005;24:3484-91.